Acquisition / Disposition · Reg FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2019   Amgen Inc. (Exact name of registrant as specified in its charter)   Delaware   001-37702   95-3540776 (State or other jurisdiction of incorporation)    (Commission File Number)    (IRS Employer Identification No.)        One Amgen Center Drive Thousand Oaks California   91320-1799 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (805) 447-1000   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   AMGN   The NASDAQ Global Select Market 1.250% Senior Notes Due 2022   AMGN22   New York Stock Exchange 2.000% Senior Notes Due 2026   AMGN26   New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐     Item 2.01 Completion of Acquisition or Disposition of Assets On November 21, 2019 (the “ Closing ”), Amgen Inc. (“ Amgen ”) completed the acquisition of certain assets and liabilities associated with the worldwide rights to OTEZLA ® (apremilast) from Celgene Corporation (“ Celgene ”) pursuant to an Asset Purchase Agreement (as amended, the “ APA ”), dated August 25, 2019, between Amgen and Celgene, a copy of which was attached to the Current Report on Form 8-K filed by Amgen on August 26, 2019. The parties entered into Amendment No. 1 to the APA on October 17, 2019, a copy of which was attached to the Current Report on Form 8-K filed by Amgen on October 18, 2019. Amgen and Celgene entered into the APA in connection with the merger between Celgene and Bristol-Myers Squibb Company, which was completed on November 20, 2019. Item 7.01. Regulation FD Disclosure. Amgen has issued a press release regarding the Closing, which is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference. The information contained in this Item 7.01 and Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”), or otherwise subject to the liabilities of such section, nor will such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired. Amgen intends to file financial statements in accordance with Item 9.01(a) as part of an amendment to this Current Report on Form 8-K no later than 71 calendar days after the required filing date for this Current Report on Form 8-K. (b) Pro Forma Financial Information. Amgen intends to file pro forma financial information in accordance with Item 9.01(b) as part of an amendment to this Current Report on Form  8-K no later than 71 days after the required filing date for this Current Report on Form 8-K. d) Exhibits Exhibit No.     Description             99.1     Press Release, dated November 21, 2019.             104     Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     AMGEN INC.               Date: November 21, 2019     By:   /s/ Jonathan P. Graham       Jonathan P. Graham Executive Vice President, General Counsel and Secretary